Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Ocular Decongestants, Sympathomimetics
Ophthalmic vasoconstrictor used for redness and lubrication
AK-Con, Albalon, All Clear, Napha Forte, Naphcon Forte, Ocu-Zoline
AK-Con/Albalon/Napha Forte/Naphazoline Hydrochloride/Naphcon Forte/Ocu-Zoline Ophthalmic Sol: 0.1%
Instill 1—2 drops in the conjunctival sac(s) every 3—4 hours as needed.
16 drops/day in each eye
16 drops/day in each eye
Safety and efficacy not established.
No dosage adjustments are needed.
AK-Con:- Storage information not availableAlbalon:- Storage information not availableAll Clear:- Store at room temperature (between 59 to 86 degrees F)All Clear AR:- Discard product if it contains particulate matter, is cloudy, or discolored- Store between 59 to 77 degrees FNapha Forte:- Storage information not availableNaphcon:- Discard product if it contains particulate matter, is cloudy, or discolored- Store at room temperature (between 59 to 86 degrees F)Naphcon Forte:- Storage information not availableOcu-Zoline :- Storage information not available
Naphazoline causes vasoconstriction of conjunctival blood vessels, which may exacerbate the effects of glaucoma; thus, use of the prescription strength ophthalmic solution (i.e., naphazoline 0.1%) is contraindicated in patients with closed-angle glaucoma. Some over-the-counter ophthalmic solutions also contain naphazoline; however, they are formulated with a lower drug concentration (i.e., naphazoline 0.03% or less). Glaucoma patients should use these OTC products only after receiving approval from their prescriber.
Naphazoline should be used cautiously in patients receiving MAOI therapy as the combination of an MAOI and a sympathomimetic drug may result in hypertensive crisis.
The safety and efficacy of naphazoline ophthalmic solution have not been established in neonates, infants, children, and adolescents. Use in pediatric patients, especially infants, may result in CNS depression leading to coma and marked reduction in body temperature.
Instruct patients to removed contact lenses prior to ophthalmic administration of naphazoline. The inactive preservative, benzalkonium chloride, may be absorbed to the surface of soft contact lenses.
Naphazoline should be used with caution in patients with hypertension or cardiac disease as systemic absorption of the drug may result in increased blood pressure and cardiac irregularities.
Naphazoline should be used with caution in thyroid disease patients with hyperthyroidism, because they can be more sensitive to catecholamines.
Naphazoline should be used with caution in patients with diabetes mellitus as systemic absorption of the drug may result in hyperglycemia.
Use naphazoline ophthalmic solution with caution in the presence of ocular infection or ocular trauma.
Naphazoline is classified as FDA pregnancy category C. It is not known if the drug can cause fetal harm when administered to a pregnant woman. Limited data have not demonstrated a clinically significant effect on the fetus during first trimester exposure of naphazoline; however, other sympathomimetic drugs have been associated with minor malformations, inguinal hernia, and clubfoot. According to the manufacturer, naphazoline should be given to a pregnant woman only if clearly needed.
According to the manufacturer, it is not known whether naphazoline is excreted in human milk. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.
keratitis / Delayed / Incidence not knownocular hypertension / Delayed / Incidence not knowncoma / Early / Incidence not knownbradycardia / Rapid / Incidence not known
hypertension / Early / Incidence not knownblurred vision / Early / Incidence not knownhyperglycemia / Delayed / Incidence not knownrespiratory depression / Rapid / Incidence not knownhypotension / Rapid / Incidence not knownsinus tachycardia / Rapid / Incidence not known
mydriasis / Early / Incidence not knownlacrimation / Early / Incidence not knownocular irritation / Rapid / Incidence not knownhyperhidrosis / Delayed / Incidence not knowndrowsiness / Early / Incidence not knownweakness / Early / Incidence not knownheadache / Early / Incidence not knowndizziness / Early / Incidence not knownnausea / Early / Incidence not knownlethargy / Early / Incidence not knownvomiting / Early / Incidence not knownhypothermia / Delayed / Incidence not known
There are no drug interactions associated with Naphazoline products.
Naphazoline stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva. Ophthalmic administration causes vasoconstriction of conjunctival blood vessels thereby decreasing conjunctival congestion. When applied topically to mucous membranes, the drug causes vasoconstriction that shrinks the mucus membranes, promotes drainage, and improves ventilation.
Naphazoline is administered ophthalmically.
Ophthalmic RouteAfter ophthalmic administration of naphazoline, local vasoconstriction usually occurs within 10 minutes and may persist for 2—6 hours.